Page last updated: 2024-10-29

iodixanol and Vascular Diseases

iodixanol has been researched along with Vascular Diseases in 2 studies

iodixanol: dimeric contrast media; structure given in first source
iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.

Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.

Research Excerpts

ExcerptRelevanceReference
" Treatment-emergent adverse events were similar between groups (iodixanol 18."2.84Randomized, Double-Blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography - The COMFORT II Trial. ( Lim, L; Lonjedo Vicent, E; Macho, J; Martínez-Rodrigo, JJ; Rosenberg, C; Todoran, TM, 2017)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rosenberg, C1
Martínez-Rodrigo, JJ1
Lonjedo Vicent, E1
Macho, J1
Lim, L1
Todoran, TM1
Drescher, P1
Knes, JM1
Madsen, PO1

Trials

1 trial available for iodixanol and Vascular Diseases

ArticleYear
Randomized, Double-Blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography - The COMFORT II Trial.
    The Journal of invasive cardiology, 2017, Volume: 29, Issue:1

    Topics: Angiography; Contrast Media; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-U

2017

Other Studies

1 other study available for iodixanol and Vascular Diseases

ArticleYear
Prevention of contrast medium-induced renal vasospasm by phosphodiesterase inhibition.
    Investigative radiology, 1998, Volume: 33, Issue:12

    Topics: Animals; Contrast Media; Diatrizoate Meglumine; Dose-Response Relationship, Drug; Drug Evaluation, P

1998